First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

The Lynx Group: 2022 Ask The Expert M Choi .pdf
Please Click the Issue to Download


This resource provides insights from a medical oncologist who specializes in gastric cancer and esophageal cancer. Here you will find information on the expanded analyses of efficacy and safety at a 24-month follow-up from Checkmate 649, a multicenter, randomized, phase 3, open-label study that evaluated OPDIVO plus capecitabine and oxaliplatin (CapeOX) or OPDIVO plus fluorouracil, leucovorin, and oxaliplatin (FOLFOX) compared with CapeOX or FOLFOX alone as first-line therapy in patients with previously untreated, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

Download to Continue Reading

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: